INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics

American Journal of Dermatopathology

Volumn 31, Issue 2, 2009, Pages 152-156

  Orrock, Jared M ^a   Abbott, Jared J ^a   Gibson, Lawrence E ^a   Folpe, Andrew L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Epithelioid sarcoma; GLUT 1; Immunohistochemistry; INI1

Indexed keywords

CD34 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; GLUCOSE TRANSPORTER 1; PROTEIN INI1; PROTEIN P63; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; CONTROLLED STUDY; DERMATOFIBROMA; EPITHELIOID SARCOMA; FASCIITIS; FIBROXANTHOMA; GRANULOMA ANNULARE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NODULAR FASCIITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID NODULE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; DIFFERENTIAL DIAGNOSIS; METABOLISM; PATHOLOGY; SARCOMA; SKIN DISEASE; SKIN TUMOR; XANTHOMATOSIS;

BIOLOGICAL MARKERS; CHROMOSOMAL PROTEINS, NON-HISTONE; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FASCIITIS; GLUCOSE TRANSPORTER TYPE 1; GRANULOMA ANNULARE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; NEOPLASMS, SQUAMOUS CELL; RHEUMATOID NODULE; SARCOMA; SKIN DISEASES; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; XANTHOMATOSIS;

EID: 67649658222     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31818a5c4f     Document Type: Article

References (35)

1. Enzinger FM. Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970;26:1029-1041.
2. Miettinen M, Fanburg-Smith JC, Virolainen M, et al. Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum Pathol. 1999;30:934-942.
3. Laskin WB, Miettinen M. Epithelioid sarcoma: new insights based on an extended immunohistochemical analysis. Arch Pathol Lab Med. 2003; 127:1161-1168.
4. Mirra JM, Kessler S, Bhuta S, et al. The fibroma-like variant of epithelioid sarcoma. A fibrohistiocytic/myoid cell lesion often confused with benign and malignant spindle cell tumors. Cancer. 1992;69:1382-1395.
5. Muchardt C, Yaniv M. When the SWI/SNF complex remodels.the cell cycle. Oncogene. 2001;20:3067-3075.
6. Medjkane S, Novikov E, Versteege I, et al. The tumor suppressor hSNF5/ INI1 modulates cell growth and actin cytoskeleton organization. Cancer Res. 2004;64:3406-3413.
7. Versteege I, Medjkane S, Rouillard D, et al. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene. 2002;21:6403-6412.
8. Judkins AR. Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol. 2007;14: 335-339.
9. Kohashi K, Oda Y, Yamamoto H, et al. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/ INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 2008;32:1168-1174.
10. Cheng JX, Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol. 2008;21:647-652.
11. Patil S, Perry A, Maccollin M, et al. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol. 2008;18:517-519.
12. Sigauke E, Rakheja D, Maddox DL, et al. Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol. 2006;19:717-725.
13. Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 2005;65:4012-4019.
14. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219: 713-725.
15. Kasahara M, Hinkle PC. Reconstitution and purification of the D-glucose transporter from human erythrocytes. J Biol Chem. 1977; 252:7384-7390.
16. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem. 1990; 265:18035-18040.
17. Mayer A, Hockel M, Vaupel P. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking? Strahlenther Onkol. 2006;182:501-510.
18. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31:11-22.
19. Leon-Villapalos J, Wolfe K, Kangesu L. GLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations. Br J Plast Surg. 2005;58:348-352.
20. Mo JQ, Dimashkieh HH, Bove KE. GLUT1 endothelial reactivity distinguishes hepatic infantile hemangioma from congenital hepatic vascular malformation with associated capillary proliferation. Hum Pathol. 2004;35:200-209.
21. Hernandez F, Navarro M, Encinas JL, et al. The role of GLUT1 immunostaining in the diagnosis and classification of liver vascular tumors in children. J Pediatr Surg. 2005;40:801-804.
22. Hirose T, Tani T, Shimada T, et al. Immunohistochemical demonstration of EMA/Glut1-positive perineurial cells and CD34-positive fibroblas-tic cells in peripheral nerve sheath tumors. Mod Pathol. 2003;16:293-298.
23. Yamaguchi U, Hasegawa T, Hirose T, et al. Sclerosing perineurioma: a clinicopathological study of five cases and diagnostic utility of immunohistochemical staining for GLUT1. Virchows Arch. 2003;443: 159-163.
24. Mentzel T, Kutzner H. Reticular and plexiform perineurioma: clinico-pathological and immunohistochemical analysis of two cases and review of perineurial neoplasms of skin and soft tissues. Virchows Arch. 2005; 447:677-682.
25. Smith ME, Awasthi R, O'Shaughnessy S, et al. Evaluation of perineurial differentiation in epithelioid sarcoma. Histopathology. 2005;47:575-581.
26. rd, Caron BL, et al. GLUT-1 expressin in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol. 2008;39:1519-1526.
27. Lin Z, Weinberg JM, Malhotra R, et al. GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation. Am J Physiol Endocrinol Metab. 2000;278:E958-E966.
28. Kalir T, Rahaman J, Hagopian G, et al. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med. 2005;129:651-654.
29. Page T, Hodgkinson AD, Ollerenshaw M, et al. Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet. 2005;163:151-155.
30. Alo PL, Visca P, Botti C, et al. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol. 2001;116:129-134.
31. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046-1051.
32. Urano N, Fujiwara Y, Doki Y, et al. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer. 2006;9: 44-49.
33. Younes M, Juarez D, Lechago LV, et al. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001;21:575-578.
34. Burstein DE, Nagi C, Kohtz DS, et al. Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization. Histopathology. 2006;48:717-722.
35. Weiss SW, Goldblum JR, Enzinger FM. Enzinger and Weiss' Soft Tissue Tumors. 5th ed. Philadelphia, PA: Mosby Elsevier; 2008.